11/20/2019  12:10:59 PM Chg. +0.0200 Volume Bid12:11:05 PM Ask12:11:05 PM Market Capitalization Dividend Y. P/E Ratio
1.9750EUR +1.02% 0
Turnover: 0.0000
1.9750Bid Size: 1,020 2.0100Ask Size: 1,000 381.09 mill.EUR 0.00% -

Business description

The Group managed by 4SC AG (ISIN DE000A14KL72) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies.
 

Management board & Supervisory board

CEO
Dr. Jason Loveridge
Management board
Dr. med. Frank Hermann, Dr. med. Susanne Danhauser-Riedl
Supervisory board
Dr. Clemens Doppler, Joerg von Petrikowsky, Dr. Irina Antonijevic, Dr. Manfred Rüdiger, Helmut Jeggle, Prof. Dr. Helga Rübsamen-Schaeff
 

Company data

Name: 4SC AG
Address: Fraunhoferstraße 22,D-82152 Planegg-Martinsried
Phone: +49-89-700763-0
Fax: +49-89-700763-29
E-mail: -
Internet: www.4sc.de
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 26.37%
IPO date: 12/15/2005

Investor relations

Name: Dr. Anna Niedl
IR phone: +49-89-700763-73
IR Fax: -
IR e-mail: anna.niedl@4sc.com

Company calendar

CW 13 | 3/25/2020 4th Quarter/Annual Report
CW 17 | 4/21/2020 Interim Report 1st Quarter/3 Months
CW 19 | 5/8/2020 General Shareholder Meeting
CW 33 | 8/11/2020 Interim Report 2nd Quarter/6 Months
CW 43 | 10/20/2020 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Santo Holding
 
37.60%
Freefloat
 
26.37%
ATS Beteiligungsverwaltung GmbH
 
22.80%
First Capital Partner GmbH
 
5.30%
Wolfgang Egger
 
4.03%
Wellington Partners
 
3.90%